Aevum Bio Labs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 32.91%
- Ebitda 39.66%
- Net Worth -0.55%
- Total Assets 9.79%
About Aevum Bio Labs
Aevum Bio Labs Private Limited (ABLPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 May 2009 and has a history of 15 years and nine months. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Cetas Bio Labs Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Satya Divi and Raja Divi serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999TG2009PTC063542
-
Company No.
063542
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 May 2009
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Aevum Bio Labs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satya Divi
|
Director | 05-May-2009 | Current |
|
Raja Divi
|
Director | 05-May-2009 | Current |
Financial Performance of Aevum Bio Labs.
Aevum Bio Labs Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 32.91% increase in profit. The company's net worth dipped by a decrease of 0.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aevum Bio Labs?
In 2021, Aevum Bio Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Reva Medical Institute Private LimitedSatya Divi is a mutual person
-
Cenaura Technologies Private LimitedSatya Divi is a mutual person
-
Shuddh Health Care Private LimitedSatya Divi is a mutual person
-
Svaasa Infra LlpSatya Divi and Raja Divi are mutual person
-
Egron Farms Private Limited
Satya Divi and Raja Divi are mutual person
-
Norge Farms Private Limited
Satya Divi and Raja Divi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aevum Bio Labs?
Unlock and access historical data on people associated with Aevum Bio Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aevum Bio Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aevum Bio Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.